GLP-1R Agonist Treatment for Opioid Use Disorder
Phase PHASE2 · RECRUITING · Sponsor: Milton S. Hershey Medical Center
Semaglutide — Evidence
Clinical trials and publications sourced from ClinicalTrials.gov, PubMed, and FDA. Updated hourly by the automated crawler.
ClinicalTrials.gov (31)
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Novo Nordisk A/S
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
Phase NA · NOT_YET_RECRUITING · Sponsor: Oelisoa Andriankaja
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Phase N/A · RECRUITING · Sponsor: Ohio State University
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
Phase PHASE2 · RECRUITING · Sponsor: Antag Therapeutics
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Phase PHASE2 · RECRUITING · Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)
Phase NA · ACTIVE_NOT_RECRUITING · Sponsor: Foundation for Atlanta Veterans Education and Research, Inc.
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
Phase PHASE1 · ACTIVE_NOT_RECRUITING · Sponsor: Boehringer Ingelheim
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
Phase N/A · ENROLLING_BY_INVITATION · Sponsor: Novo Nordisk A/S
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Novo Nordisk A/S
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Novo Nordisk A/S
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Phase PHASE2 · ACTIVE_NOT_RECRUITING · Sponsor: University of California, San Diego
Semaglutide Therapy for Alcohol Reduction (STAR)
Phase PHASE2 · RECRUITING · Sponsor: National Institute on Drug Abuse (NIDA)
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Phase PHASE2 · ACTIVE_NOT_RECRUITING · Sponsor: Regeneron Pharmaceuticals
Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide
Phase NA · RECRUITING · Sponsor: Sheba Medical Center
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Phase PHASE3 · COMPLETED · Sponsor: Novo Nordisk A/S
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Phase PHASE2 · RECRUITING · Sponsor: Eli Lilly and Company
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
Phase N/A · RECRUITING · Sponsor: John Bauer
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
Phase PHASE2/PHASE3 · RECRUITING · Sponsor: University of Colorado, Denver
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Phase PHASE4 · ENROLLING_BY_INVITATION · Sponsor: Mayo Clinic
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder
Phase PHASE3 · NOT_YET_RECRUITING · Sponsor: VA Office of Research and Development
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Phase PHASE1 · RECRUITING · Sponsor: Novo Nordisk A/S
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Phase PHASE3 · RECRUITING · Sponsor: Novo Nordisk A/S
Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
Phase N/A · RECRUITING · Sponsor: University of Alberta
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Phase PHASE3 · RECRUITING · Sponsor: Kailera
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
Phase PHASE3 · NOT_YET_RECRUITING · Sponsor: Population Health Research Institute
Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
Phase NA · NOT_YET_RECRUITING · Sponsor: Hallym University
Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?
Phase NA · NOT_YET_RECRUITING · Sponsor: Knut Mai
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
Phase NA · NOT_YET_RECRUITING · Sponsor: Tianjin Medical University
Effects of GLP-1 RAs on Human Lactation Outcomes
Phase N/A · RECRUITING · Sponsor: University of Colorado, Denver
Salivary Function and Dental Changes During GLP-1 Therapy
Phase N/A · NOT_YET_RECRUITING · Sponsor: Bilecik Seyh Edebali Universitesi
PubMed (47)
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery · 2026 Jul 16 · DOI: 10.1016/j.ejvs.2026.07.037
Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
British journal of clinical pharmacology · 2026 Jul 16 · DOI: 10.1002/bcp.70711
Trends in Usage and Payments for Glucagon-Like Peptide-1 Receptor Agonists in the United States, 2017 to 2022: A Nationally Representative Repeated Cross-Sectional Study.
Journal of the American Heart Association · 2026 Jul 17 · DOI: 10.1161/JAHA.125.046302
Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.
Cureus · 2026 Jun · DOI: 10.7759/cureus.110952
Semaglutide-Induced Ischemic Colitis in A Middle-Aged Female Without Vascular Risk Factors.
European journal of case reports in internal medicine · 2026 · DOI: 10.12890/2026_006649
Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy.
Frontiers in endocrinology · 2026 · DOI: 10.3389/fendo.2026.1870649
Effect of semaglutide on hidradenitis suppurativa disease control and quality of life: A case series.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 Jul 17 · DOI: 10.1111/jdv.70614
Peripheral artery disease: advances in medical therapy.
European heart journal · 2026 Jul 17 · DOI: 10.1093/eurheartj/ehag516
Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.
Surgical endoscopy · 2026 Jul 17 · DOI: 10.1007/s00464-026-13147-z
Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.
JAMA health forum · 2026 Jul 2 · DOI: 10.1001/jamahealthforum.2026.2207
N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement.
Cell reports · 2026 Jul 17 · DOI: 10.1016/j.celrep.2026.117718
Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications.
Current opinion in HIV and AIDS · 2026 Jul 17 · DOI: 10.1097/COH.0000000000001059
Therapeutic Benefit or Ocular Risk? Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy: Retraction.
Retina (Philadelphia, Pa.) · 2026 Aug 1 · DOI: 10.1097/IAE.0000000000004884
Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026 Jul 7 · DOI: 10.1016/j.numecd.2026.104859
Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026 Jul 16 · DOI: 10.1016/j.numecd.2026.104872
GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.
Multiple sclerosis and related disorders · 2026 Jul 10 · DOI: 10.1016/j.msard.2026.107388
Semaglutide promotes angiogenesis and blood-brain barrier repair after traumatic brain injury via PDGF-BB/PDGFRβ/Ang1/Tie2/VEGF signaling pathway.
Scientific reports · 2026 Jul 18 · DOI: 10.1038/s41598-026-62312-w
Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.
Diabetes, obesity & metabolism · 2026 Jul 19 · DOI: 10.1111/dom.71076
GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.
The Journal of clinical psychiatry · 2026 Jul 15 · DOI: 10.4088/JCP.25m16212
Affordable Semaglutide in India: Expanding Access and Unanswered Questions for Children and Special Populations.
Indian pediatrics · 2026 Jul 20 · DOI: 10.1007/s13312-026-00408-2
Pre-operative concerns and post-operative satisfaction: comparing attitudes toward bariatric surgery and medication intervention for weight loss on Reddit.
Surgical endoscopy · 2026 Jul 20 · DOI: 10.1007/s00464-026-13149-x
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?
The Journal of clinical endocrinology and metabolism · 2026 Jul 21 · DOI: 10.1210/clinem/dgag290
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
Annals of the American Thoracic Society · 2026 Jul 21 · DOI: 10.1093/annalsats/aaoag177
GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
Biological psychiatry · 2026 Jul 21 · DOI: 10.1016/j.biopsych.2026.06.033
From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists.
Translational research : the journal of laboratory and clinical medicine · 2026 Jul 21 · DOI: 10.1016/j.trsl.2026.07.008
Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.
BMJ open · 2026 Jul 21 · DOI: 10.1136/bmjopen-2025-109259
Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models.
Nature communications · 2026 Jul 21 · DOI: 10.1038/s41467-026-75202-6
Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
Diabetes, obesity & metabolism · 2026 Jul 21 · DOI: 10.1111/dom.71138
Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
Indian journal of orthopaedics · 2026 Jul · DOI: 10.1007/s43465-025-01614-z
Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026 Jul 20 · DOI: 10.1177/87551225261466571
Implications of Generic Semaglutide Availability on the Cost-Effectiveness of GLP-1RA for Guideline-Indicated Patients With Type 2 Diabetes.
The Canadian journal of cardiology · 2026 Jul 22 · DOI: 10.1016/j.cjca.2026.05.013
Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.
Obesity surgery · 2026 Jul 22 · DOI: 10.1007/s11695-026-08854-4
Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.
Pharmacological reports : PR · 2026 Jul 22 · DOI: 10.1007/s43440-026-00879-x
Hormonal Contraception and Initiation of Semaglutide Therapy.
JAMA network open · 2026 Jul 1 · DOI: 10.1001/jamanetworkopen.2026.24382
Can semaglutide influence tumor biomarkers? Insight from a clinical case.
Journal of food and drug analysis · 2026 Jun 15 · DOI: 10.38212/2224-6614.3594
When Side Effects Become Therapies: A Mechanistic Taxonomy of Adverse Drug Reactions as Translational Signals for Drug Repositioning.
Fundamental & clinical pharmacology · 2026 Jul · DOI: 10.1111/fcp.70109
Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder - A narrative review of available clinical evidence.
Biological psychiatry · 2026 Jul 22 · DOI: 10.1016/j.biopsych.2026.07.010
AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models.
Nature communications · 2026 Jul 22 · DOI: 10.1038/s41467-026-73370-z
The silent rise of self-prescribed semaglutide use among non-obese young adults in the Middle East.
Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit · 2026 Jun 28 · DOI: 10.26719/2026.32.6.394
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
Clinical case reports · 2026 Jul · DOI: 10.1002/ccr3.73183
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
Journal of the Endocrine Society · 2026 Aug · DOI: 10.1210/jendso/bvag149
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.
JACC. Advances · 2026 Jul · DOI: 10.1016/j.jacadv.2026.102917
Advances in proteomics research related to semaglutide: evidence from humans and animals.
Journal of endocrinological investigation · 2026 Jul 23 · DOI: 10.1007/s40618-026-02989-y
Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.
BMJ open · 2026 Jul 23 · DOI: 10.1136/bmjopen-2026-118191
Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study.
Internal and emergency medicine · 2026 Jul 23 · DOI: 10.1007/s11739-026-04468-x
Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111322
Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111363